Want to see IN:BIOFILCHEM full AI Analyst Report?
BIOFILCHEM Stock Chart & Stats
₹31.98
₹0.75(2.34%)
At close: 4:00 PM EDT
₹31.98
₹0.75(2.34%)
Day’s Range― - ―
52-Week Range₹25.60 - ₹46.82
Previous CloseN/A
Volume6.29K
Average Volume (3M)1.52K
Market Cap
₹480.08M
Enterprise Value₹418.10M
Total Cash (Recent Filing)₹33.26M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)99.0
Beta1.47
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.30
Shares Outstanding16,273,800
10 Day Avg. Volume1,221
30 Day Avg. Volume1,519
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.95
Price to Sales (P/S)1.48
P/FCF Ratio-51.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageLow leverage provides a relatively strong financial cushion compared with a heavily indebted business. It can preserve borrowing capacity, reduce interest burden, and give management more flexibility to fund operations or respond to weaker profitability over the next several quarters.
Growing Equity BaseAn expanding equity base strengthens the company’s balance-sheet foundation and can improve resilience when operating performance is volatile. Greater capitalization may also support continued investment and reduce dependence on external borrowing if cash generation remains uneven.
Positive Net ProfitabilityThe reported 2026 net margin indicates that the company remained profitable at the bottom line during the latest period. If this profitability can be supported by stronger operating performance, it could provide internal capital for business continuity and future investment.
Bears Say
Sharp Revenue DeclineA steep year-over-year revenue contraction weakens near-term operating leverage and makes future performance harder to forecast. Persistent volatility can reduce the benefits of scale, pressure resource allocation, and limit management’s ability to build a stable earnings base.
Margin CompressionThe sustained decline in gross and EBITDA margins shows that a smaller share of revenue is converting into operating profit. Thin margins leave less protection against further cost pressure and make earnings more sensitive to changes in revenue or operating conditions.
Inconsistent Cash ConversionRepeated negative operating and free cash flow indicates that reported earnings are not consistently converting into cash. This can constrain self-funded growth, increase reliance on financing, and make the company less resilient if weak cash generation persists alongside compressed margins.
Biofil Chemicals & Pharmaceuticals Ltd. News
BIOFILCHEM FAQ
What was Biofil Chemicals & Pharmaceuticals Ltd.’s price range in the past 12 months?
Biofil Chemicals & Pharmaceuticals Ltd. lowest stock price was ₹25.60 and its highest was ₹46.82 in the past 12 months.
What is Biofil Chemicals & Pharmaceuticals Ltd.’s market cap?
Biofil Chemicals & Pharmaceuticals Ltd.’s market cap is ₹480.08M.
When is Biofil Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date?
Biofil Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 14 days.
How were Biofil Chemicals & Pharmaceuticals Ltd.’s earnings last quarter?
Biofil Chemicals & Pharmaceuticals Ltd. released its earnings results on Aug 11, 2026. The company reported ₹0.067 earnings per share for the quarter.
Is Biofil Chemicals & Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Biofil Chemicals & Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Biofil Chemicals & Pharmaceuticals Ltd. pay dividends?
Biofil Chemicals & Pharmaceuticals Ltd. does not currently pay dividends.
What is Biofil Chemicals & Pharmaceuticals Ltd.’s EPS estimate?
Biofil Chemicals & Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biofil Chemicals & Pharmaceuticals Ltd. have?
Biofil Chemicals & Pharmaceuticals Ltd. has 16,273,800 shares outstanding.
What happened to Biofil Chemicals & Pharmaceuticals Ltd.’s price movement after its last earnings report?
Biofil Chemicals & Pharmaceuticals Ltd. reported an EPS of ₹0.067 in its last earnings report. Following the earnings report the stock price went down -1.061%.
Which hedge fund is a major shareholder of Biofil Chemicals & Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:BIOFILCHEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biofil Chemicals & Pharmaceuticals Ltd.
Biofil Chemicals and Pharmaceuticals Limited, headquartered in Indore, India, is primarily involved in the country's pharmaceutical and chemical industries. This company supplies a comprehensive array of fundamental drugs and chemical compounds, including sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride. Additionally, its product line features plastic dippers and caps. Beyond its product offerings, Biofil also provides contract manufacturing services for pharmaceutical items. The company was founded in 1985.
Technical Analysis
Krebs Biochemicals & Industries Ltd.
―
Lasa Supergenerics Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Par Drugs and Chemicals Limited
―
Vivimed Labs Limited
―